[1]
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®): Health Professional Version 2002;
[PubMed PMID: 26389443]
[2]
Modugno F,Edwards RP, Ovarian cancer: prevention, detection, and treatment of the disease and its recurrence. Molecular mechanisms and personalized medicine meeting report. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2012 Oct;
[PubMed PMID: 23013733]
Level 2 (mid-level) evidence
[3]
Mancari R,Cutillo G,Bruno V,Vincenzoni C,Mancini E,Baiocco E,Bruni S,Vocaturo G,Chiofalo B,Vizza E, Development of new medical treatment for epithelial ovarian cancer recurrence. Gland surgery. 2020 Aug;
[PubMed PMID: 32953630]
[4]
Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. International journal of women's health. 2019:11():287-299. doi: 10.2147/IJWH.S197604. Epub 2019 Apr 30
[PubMed PMID: 31118829]
[5]
Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. CA: a cancer journal for clinicians. 2018 Jul:68(4):284-296. doi: 10.3322/caac.21456. Epub 2018 May 29
[PubMed PMID: 29809280]
[6]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: a cancer journal for clinicians. 2020 Jan:70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8
[PubMed PMID: 31912902]
[7]
Kurman RJ, Shih IeM. The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. The American journal of pathology. 2016 Apr:186(4):733-47. doi: 10.1016/j.ajpath.2015.11.011. Epub
[PubMed PMID: 27012190]
[8]
Rosen DG, Yang G, Liu G, Mercado-Uribe I, Chang B, Xiao XS, Zheng J, Xue FX, Liu J. Ovarian cancer: pathology, biology, and disease models. Frontiers in bioscience (Landmark edition). 2009 Jan 1:14(6):2089-102. doi: 10.2741/3364. Epub 2009 Jan 1
[PubMed PMID: 19273186]
[9]
Stewart C, Ralyea C, Lockwood S. Ovarian Cancer: An Integrated Review. Seminars in oncology nursing. 2019 Apr:35(2):151-156. doi: 10.1016/j.soncn.2019.02.001. Epub 2019 Mar 11
[PubMed PMID: 30867104]
[10]
Moreno-Bueno G, Gamallo C, Pérez-Gallego L, de Mora JC, Suárez A, Palacios J. beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagnostic molecular pathology : the American journal of surgical pathology, part B. 2001 Jun:10(2):116-22
[PubMed PMID: 11385321]
[11]
Babaier A, Ghatage P. Mucinous Cancer of the Ovary: Overview and Current Status. Diagnostics (Basel, Switzerland). 2020 Jan 19:10(1):. doi: 10.3390/diagnostics10010052. Epub 2020 Jan 19
[PubMed PMID: 31963927]
Level 3 (low-level) evidence
[12]
Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet (London, England). 2019 Mar 23:393(10177):1240-1253. doi: 10.1016/S0140-6736(18)32552-2. Epub
[PubMed PMID: 30910306]
[13]
Smith CG. A Resident's Perspective of Ovarian Cancer. Diagnostics (Basel, Switzerland). 2017 Apr 27:7(2):. doi: 10.3390/diagnostics7020024. Epub 2017 Apr 27
[PubMed PMID: 28448435]
Level 3 (low-level) evidence
[14]
Renjen PN, Chaudhari DM, Shilpi US, Zutshi D, Ahmad K. Paraneoplastic Cerebellar Degeneration Associated With Ovarian Adenocarcinoma: A Case Report and Review of Literature. Annals of Indian Academy of Neurology. 2018 Oct-Dec:21(4):311-314. doi: 10.4103/aian.AIAN_411_17. Epub
[PubMed PMID: 30532364]
Level 3 (low-level) evidence
[16]
Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. Journal of ovarian research. 2019 Mar 27:12(1):28. doi: 10.1186/s13048-019-0503-7. Epub 2019 Mar 27
[PubMed PMID: 30917847]
[17]
Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC Jr, Skates SJ. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecologic oncology. 2009 Jan:112(1):40-6. doi: 10.1016/j.ygyno.2008.08.031. Epub 2008 Oct 12
[PubMed PMID: 18851871]
[18]
Whitwell HJ, Worthington J, Blyuss O, Gentry-Maharaj A, Ryan A, Gunu R, Kalsi J, Menon U, Jacobs I, Zaikin A, Timms JF. Improved early detection of ovarian cancer using longitudinal multimarker models. British journal of cancer. 2020 Mar:122(6):847-856. doi: 10.1038/s41416-019-0718-9. Epub 2020 Jan 15
[PubMed PMID: 31937926]
[19]
Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Oct 1:34(28):3460-73. doi: 10.1200/JCO.2016.68.6907. Epub 2016 Aug 8
[PubMed PMID: 27502591]
Level 1 (high-level) evidence
[20]
Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, Jayson GC, Johnson N, Swart AM, Verheijen R, McCluggage WG, Perren T, Panici PB, Kenter G, Casado A, Mendiola C, Stuart G, Reed NS, Kehoe S, EORTC, MRC CHORUS study investigators. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. The Lancet. Oncology. 2018 Dec:19(12):1680-1687. doi: 10.1016/S1470-2045(18)30566-7. Epub 2018 Nov 6
[PubMed PMID: 30413383]
[21]
van Meurs HS, Tajik P, Hof MH, Vergote I, Kenter GG, Mol BW, Buist MR, Bossuyt PM. Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial. European journal of cancer (Oxford, England : 1990). 2013 Oct:49(15):3191-201. doi: 10.1016/j.ejca.2013.06.013. Epub 2013 Jul 11
[PubMed PMID: 23850170]
Level 1 (high-level) evidence
[22]
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Mar 1:20(5):1248-59
[PubMed PMID: 11870167]
Level 1 (high-level) evidence
[23]
Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ (Clinical research ed.). 2020 Nov 9:371():m3773. doi: 10.1136/bmj.m3773. Epub 2020 Nov 9
[PubMed PMID: 33168565]
[24]
Lawrie TA, Winter-Roach BA, Heus P, Kitchener HC. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. The Cochrane database of systematic reviews. 2015 Dec 17:2015(12):CD004706. doi: 10.1002/14651858.CD004706.pub5. Epub 2015 Dec 17
[PubMed PMID: 26676202]
Level 1 (high-level) evidence
[25]
Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, Pecorelli S, EORTC-ACTION collaborators. European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. Journal of the National Cancer Institute. 2003 Jan 15:95(2):113-25
[PubMed PMID: 12529344]
[26]
Monk BJ, Chan JK. Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer? Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Nov 1:28(suppl_8):viii40-viii45. doi: 10.1093/annonc/mdx451. Epub
[PubMed PMID: 29232474]
[27]
Armstrong DK, Walker JL. Role of Intraperitoneal Therapy in the Initial Management of Ovarian Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Sep 20:37(27):2416-2419. doi: 10.1200/JCO.19.00671. Epub 2019 Aug 12
[PubMed PMID: 31403863]
[28]
Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, DiSilvestro PA, Fujiwara K, Alberts DS, Zheng W, Tewari KS, Cohn DE, Powell MA, Van Le L, Davidson SA, Gray HJ, Rose PG, Aghajanian C, Myers T, Alvarez Secord A, Rubin SC, Mannel RS. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Jun 1:37(16):1380-1390. doi: 10.1200/JCO.18.01568. Epub 2019 Apr 19
[PubMed PMID: 31002578]
Level 1 (high-level) evidence
[29]
Pignata S, Di Maio M, Gallo C, Perrone F. Carboplatin plus paclitaxel scheduling for advanced ovarian cancer - authors' reply. The Lancet. Oncology. 2014 Jun:15(7):e250-1. doi: 10.1016/S1470-2045(14)70219-0. Epub
[PubMed PMID: 24872107]
[30]
Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F, Multicentre Italian Trials in Ovarian cancer (MITO-7), Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO), Mario Negri Gynecologic Oncology (MaNGO), European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10), Gynecologic Cancer InterGroup (GCIG) Investigators. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. The Lancet. Oncology. 2014 Apr:15(4):396-405. doi: 10.1016/S1470-2045(14)70049-X. Epub 2014 Feb 28
[PubMed PMID: 24582486]
Level 1 (high-level) evidence
[31]
von Gruenigen VE, Huang HQ, Beumer JH, Lankes HA, Tew W, Herzog T, Hurria A, Mannel RS, Rizack T, Landrum LM, Rose PG, Salani R, Bradley WH, Rutherford TJ, Higgins RV, Secord AA, Fleming G. Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. Gynecologic oncology. 2017 Mar:144(3):459-467. doi: 10.1016/j.ygyno.2016.11.033. Epub 2017 Jan 13
[PubMed PMID: 28089376]
[32]
Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, Jiang C, Alberts D, Southwest Oncology Group, Gynecologic Oncology Group. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Jul 1:21(13):2460-5
[PubMed PMID: 12829663]
Level 1 (high-level) evidence
[33]
Mannel RS, Brady MF, Kohn EC, Hanjani P, Hiura M, Lee R, Degeest K, Cohn DE, Monk BJ, Michael H. A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecologic oncology. 2011 Jul:122(1):89-94. doi: 10.1016/j.ygyno.2011.03.013. Epub 2011 May 6
[PubMed PMID: 21529904]
Level 1 (high-level) evidence
[34]
Khalique S, Hook JM, Ledermann JA. Maintenance therapy in ovarian cancer. Current opinion in oncology. 2014 Sep:26(5):521-8. doi: 10.1097/CCO.0000000000000110. Epub
[PubMed PMID: 25033374]
Level 3 (low-level) evidence
[35]
du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P. Incorporation of pazopanib in maintenance therapy of ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Oct 20:32(30):3374-82. doi: 10.1200/JCO.2014.55.7348. Epub 2014 Sep 15
[PubMed PMID: 25225436]
[36]
Ferriss JS, Java JJ, Bookman MA, Fleming GF, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente MP, Burger RA. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study. Gynecologic oncology. 2015 Oct:139(1):17-22. doi: 10.1016/j.ygyno.2015.07.103. Epub 2015 Jul 26
[PubMed PMID: 26216729]
[37]
Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. The New England journal of medicine. 2018 Dec 27:379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21
[PubMed PMID: 30345884]
[38]
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P, PAOLA-1 Investigators. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. The New England journal of medicine. 2019 Dec 19:381(25):2416-2428. doi: 10.1056/NEJMoa1911361. Epub
[PubMed PMID: 31851799]
[39]
Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. The New England journal of medicine. 2019 Dec 19:381(25):2403-2415. doi: 10.1056/NEJMoa1909707. Epub 2019 Sep 28
[PubMed PMID: 31562800]
[40]
González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ, PRIMA/ENGOT-OV26/GOG-3012 Investigators. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. The New England journal of medicine. 2019 Dec 19:381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28
[PubMed PMID: 31562799]
[41]
Palaia I, Tomao F, Sassu CM, Musacchio L, Benedetti Panici P. Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches. OncoTargets and therapy. 2020:13():6109-6129. doi: 10.2147/OTT.S205950. Epub 2020 Jun 26
[PubMed PMID: 32617007]
Level 3 (low-level) evidence
[42]
Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Therapeutic advances in medical oncology. 2014 Sep:6(5):229-39. doi: 10.1177/1758834014544121. Epub
[PubMed PMID: 25342990]
Level 3 (low-level) evidence
[43]
Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. The New England journal of medicine. 2019 Nov 14:381(20):1929-1939. doi: 10.1056/NEJMoa1902626. Epub
[PubMed PMID: 31722153]
Level 3 (low-level) evidence
[44]
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P, SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet. Oncology. 2017 Sep:18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25
[PubMed PMID: 28754483]
Level 1 (high-level) evidence
[45]
Hogen L, Thomas G, Bernardini M, Bassiouny D, Brar H, Gien LT, Rosen B, Le L, Vicus D. The effect of adjuvant radiation on survival in early stage clear cell ovarian carcinoma. Gynecologic oncology. 2016 Nov:143(2):258-263. doi: 10.1016/j.ygyno.2016.09.006. Epub 2016 Sep 9
[PubMed PMID: 27623251]
[46]
Fields EC, McGuire WP, Lin L, Temkin SM. Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future. Frontiers in oncology. 2017:7():177. doi: 10.3389/fonc.2017.00177. Epub 2017 Aug 21
[PubMed PMID: 28871275]
[47]
Brown AP, Jhingran A, Klopp AH, Schmeler KM, Ramirez PT, Eifel PJ. Involved-field radiation therapy for locoregionally recurrent ovarian cancer. Gynecologic oncology. 2013 Aug:130(2):300-5. doi: 10.1016/j.ygyno.2013.04.469. Epub 2013 May 4
[PubMed PMID: 23648467]
[48]
Machida S, Takei Y, Yoshida C, Takahashi Y, Koyanagi T, Sato N, Taneichi A, Saga Y, Fujiwara H, Suzuki M. Radiation therapy for chemotherapy-resistant recurrent epithelial ovarian cancer. Oncology. 2014:86(4):232-8. doi: 10.1159/000357269. Epub 2014 May 13
[PubMed PMID: 24853194]
[49]
Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet (London, England). 2014 Oct 11:384(9951):1376-88. doi: 10.1016/S0140-6736(13)62146-7. Epub 2014 Apr 21
[PubMed PMID: 24767708]
[50]
Griffiths RW, Zee YK, Evans S, Mitchell CL, Kumaran GC, Welch RS, Jayson GC, Clamp AR, Hasan J. Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2011 Jan:21(1):58-65. doi: 10.1097/IGC.0b013e3182049273. Epub
[PubMed PMID: 21178570]
Level 2 (mid-level) evidence
[51]
Chang SJ, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecologic oncology. 2013 Sep:130(3):493-8. doi: 10.1016/j.ygyno.2013.05.040. Epub 2013 Jun 6
[PubMed PMID: 23747291]
Level 1 (high-level) evidence
[52]
Herrinton LJ, Neslund-Dudas C, Rolnick SJ, Hornbrook MC, Bachman DJ, Darbinian JA, Jackson JM, Coughlin SS. Complications at the end of life in ovarian cancer. Journal of pain and symptom management. 2007 Sep:34(3):237-43
[PubMed PMID: 17606360]
[53]
Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha JK, Ahmad S, Basha R. Ovarian cancer: Current status and strategies for improving therapeutic outcomes. Cancer medicine. 2019 Nov:8(16):7018-7031. doi: 10.1002/cam4.2560. Epub 2019 Sep 27
[PubMed PMID: 31560828]
[54]
White KM, Seale H, Harrison R. Enhancing ovarian cancer care: a systematic review of guideline adherence and clinical variation. BMC public health. 2019 Mar 12:19(1):296. doi: 10.1186/s12889-019-6633-4. Epub 2019 Mar 12
[PubMed PMID: 30866891]
Level 1 (high-level) evidence
[55]
Bristow RE, Chang J, Ziogas A, Randall LM, Anton-Culver H. High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease. Gynecologic oncology. 2014 Feb:132(2):403-10. doi: 10.1016/j.ygyno.2013.12.017. Epub 2013 Dec 20
[PubMed PMID: 24361578]
[56]
Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ. Early palliative care for patients with metastatic non-small-cell lung cancer. The New England journal of medicine. 2010 Aug 19:363(8):733-42. doi: 10.1056/NEJMoa1000678. Epub
[PubMed PMID: 20818875]
[57]
Bakitas MA, Tosteson TD, Li Z, Lyons KD, Hull JG, Li Z, Dionne-Odom JN, Frost J, Dragnev KH, Hegel MT, Azuero A, Ahles TA. Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 May 1:33(13):1438-45. doi: 10.1200/JCO.2014.58.6362. Epub 2015 Mar 23
[PubMed PMID: 25800768]
Level 1 (high-level) evidence
[58]
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA: a cancer journal for clinicians. 2024 Jan-Feb:74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17
[PubMed PMID: 38230766]
[59]
Nash Z, Menon U. Ovarian cancer screening: Current status and future directions. Best practice & research. Clinical obstetrics & gynaecology. 2020 May:65():32-45. doi: 10.1016/j.bpobgyn.2020.02.010. Epub 2020 Mar 3
[PubMed PMID: 32273169]
Level 3 (low-level) evidence
[60]
Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, Carlino G, Taylor J, Massingham SK, Raikou M, Kalsi JK, Woolas R, Manchanda R, Arora R, Casey L, Dawnay A, Dobbs S, Leeson S, Mould T, Seif MW, Sharma A, Williamson K, Liu Y, Fallowfield L, McGuire AJ, Campbell S, Skates SJ, Jacobs IJ, Parmar M. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet (London, England). 2021 Jun 5:397(10290):2182-2193. doi: 10.1016/S0140-6736(21)00731-5. Epub 2021 May 12
[PubMed PMID: 33991479]
Level 1 (high-level) evidence
[61]
Giannini A, Di Dio C, Di Donato V, D'oria O, Salerno MG, Capalbo G, Cuccu I, Perniola G, Muzii L, Bogani G. PARP Inhibitors in Newly Diagnosed and Recurrent Ovarian Cancer. American journal of clinical oncology. 2023 Sep 1:46(9):414-419. doi: 10.1097/COC.0000000000001024. Epub 2023 Jun 12
[PubMed PMID: 37314974]
[62]
Wang JY, Gross M, Urban RR, Jorge S. Intraperitoneal and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Ovarian Cancer. Current treatment options in oncology. 2024 Mar:25(3):313-329. doi: 10.1007/s11864-023-01171-3. Epub 2024 Jan 4
[PubMed PMID: 38270801]